Literature DB >> 23335324

Role of parathyroid hormone therapy in reversing radiation-induced nonunion and normalization of radiomorphometrics in a murine mandibular model of distraction osteogenesis.

K Kelly Gallagher1, Sagar Deshpande, Catherine N Tchanque-Fossuo, Alexis Donneys, Deniz Sarhaddi, Noah S Nelson, Douglas B Chepeha, Steven R Buchman.   

Abstract

BACKGROUND: The use of mandibular distraction osteogenesis (MDO) for tissue replacement after oncologic resection or for defects caused by osteoradionecrosis has been described but, in fact, has seen limited clinical utility. Previous laboratory work has shown that radiation (XRT) causes decreased union formation, decreased cellularity, and decreased mineral density in an animal model of MDO. Our global hypothesis is that radiation-induced bone damage is partly driven by the pathologic depletion of both the number and function of osteogenic cells. Parathyroid hormone (PTH) is a U.S. Food and Drug Administration-approved anabolic hormonal therapy that has demonstrated efficacy for increasing bone mineral density for the treatment of osteoporosis. We postulate that intermittent systemic administration of PTH will serve as an anabolic stimulant to cellular function that will act to reverse radiation-induced damage and enhance bone regeneration in a murine mandibular model of DO.
METHODS: A total of 20 isogenic male Lewis rats were randomly assigned into 3 groups. Group 1 (XRT-DO, n = 7) and group 2 (XRT-DO-PTH, n = 5) received a human bioequivalent dose of 70 Gy fractionated over 5 days. All groups including group 3 (DO, n = 8) underwent a left unilateral mandibular osteotomy with bilateral external fixator placement. Four days later, mandibular DO was performed at a rate of 0.3 mm every 12 hours to reach a maximum gap of 5.1 mm. Group 2 was injected PTH (60 μg/kg) subcutaneously daily for 3 weeks following the start of MDO. On postoperative day 41, all left hemimandibles were harvested. Micro-CT at 45-μm voxel size was performed and radiomorphometrics parameters of bone mineralization were generated. Union quality was evaluated on a 4-point qualitative grading scale. Radiomorphometric data were analyzed using 1-way ANOVA, and union quality assessment was analyzed via the Mann-Whitney test. Statistical significance was considered at p ≤ .05.
RESULTS: Groups 1 and 2 appropriately demonstrated clinical signs of radiation-induced stress ranging from alopecia to mucositis. Union quality was significantly higher in PTH-treated XRT-DO animals, compared with XRT-DO group animals (p = .02). Mineralization metrics, including bone volume fraction (BVF) and bone mineral density (BMD), also showed statistically significant improvement. The groups that were treated with PTH showed no statistical differences in union or radiomorphometrics when compared with DO in nonradiated animals.
CONCLUSION: We have successfully demonstrated the therapeutic efficacy of PTH to stimulate and enhance bone regeneration in our irradiated murine mandibular model of DO. Our investigation effectively resulted in statistically significant increases in BMD, BVF, and clinical unions in PTH-treated mandibles. PTH demonstrates immense potential to treat clinical pathologies where remediation of bone regeneration is essential.
Copyright © 2013 Wiley Periodicals, Inc., A Wiley Company.

Entities:  

Keywords:  distraction osteogenesis; mandible; mineral density; parathyroid hormone; radiation

Mesh:

Substances:

Year:  2013        PMID: 23335324      PMCID: PMC4160101          DOI: 10.1002/hed.23216

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  27 in total

1.  Radiation effects on osteoblasts in vitro: a potential role in osteoradionecrosis.

Authors:  T J Gal; T Munoz-Antonia; C A Muro-Cacho; D W Klotch
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2000-09

Review 2.  Craniofacial distraction osteogenesis: a review of the literature: Part 1: clinical studies.

Authors:  G Swennen; H Schliephake; R Dempf; H Schierle; C Malevez
Journal:  Int J Oral Maxillofac Surg       Date:  2001-04       Impact factor: 2.789

3.  Dose-response effect of human equivalent radiation in the murine mandible: part I. A histomorphometric assessment.

Authors:  Catherine N Tchanque-Fossuo; Laura A Monson; Aaron S Farberg; Alexis Donneys; Aria J Zehtabzadeh; Elizabeth R Razdolsky; Steven R Buchman
Journal:  Plast Reconstr Surg       Date:  2011-07       Impact factor: 4.730

Review 4.  Anabolic effect of parathyroid hormone on cancellous and cortical bone histology.

Authors:  M Gunness; J M Hock
Journal:  Bone       Date:  1993 May-Jun       Impact factor: 4.398

5.  Unique rodent model of distraction osteogenesis of the mandible.

Authors:  Steven R Buchman; Michael A Ignelzi; Caius Radu; Jonathan Wilensky; Andrew H Rosenthal; Lawrence Tong; Samuel T Rhee; Steven A Goldstein
Journal:  Ann Plast Surg       Date:  2002-11       Impact factor: 1.539

Review 6.  Distraction osteogenesis of the craniofacial skeleton.

Authors:  J G McCarthy; E J Stelnicki; B J Mehrara; M T Longaker
Journal:  Plast Reconstr Surg       Date:  2001-06       Impact factor: 4.730

7.  Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.

Authors:  R M Neer; C D Arnaud; J R Zanchetta; R Prince; G A Gaich; J Y Reginster; A B Hodsman; E F Eriksen; S Ish-Shalom; H K Genant; O Wang; B H Mitlak
Journal:  N Engl J Med       Date:  2001-05-10       Impact factor: 91.245

Review 8.  Radiotherapy-induced mandibular bone complications.

Authors:  Barbara A Jereczek-Fossa; Roberto Orecchia
Journal:  Cancer Treat Rev       Date:  2002-02       Impact factor: 12.111

9.  The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis.

Authors:  Dennis M Black; Susan L Greenspan; Kristine E Ensrud; Lisa Palermo; Joan A McGowan; Thomas F Lang; Patrick Garnero; Mary L Bouxsein; John P Bilezikian; Clifford J Rosen
Journal:  N Engl J Med       Date:  2003-09-20       Impact factor: 91.245

10.  Intermittent parathyroid hormone (1-34) enhances mechanical strength and density of new bone after distraction osteogenesis in rats.

Authors:  C Seebach; R Skripitz; T T Andreassen; P Aspenberg
Journal:  J Orthop Res       Date:  2004-05       Impact factor: 3.494

View more
  6 in total

1.  Parathyroid hormone attenuates radiation-induced increases in collagen crosslink ratio at periosteal surfaces of mouse tibia.

Authors:  Megan E Oest; Bo Gong; Karen Esmonde-White; Kenneth A Mann; Nicholas D Zimmerman; Timothy A Damron; Michael D Morris
Journal:  Bone       Date:  2016-03-04       Impact factor: 4.398

Review 2.  Current concepts of bone tissue engineering for craniofacial bone defect repair.

Authors:  Brian Alan Fishero; Nikita Kohli; Anusuya Das; John Jared Christophel; Quanjun Cui
Journal:  Craniomaxillofac Trauma Reconstr       Date:  2014-11-18

Review 3.  Application of chemical factors for acceleration of consolidation phase of the distraction osteogenesis: a scoping review.

Authors:  Sadra Mohaghegh; Fatemeh Alirezaei; Nima Ahmadi; Farnaz Kouhestani; Saeed Reza Motamedian
Journal:  Oral Maxillofac Surg       Date:  2022-07-19

4.  PTH1-34 alleviates radiotherapy-induced local bone loss by improving osteoblast and osteocyte survival.

Authors:  Abhishek Chandra; Tiao Lin; Mary Beth Tribble; Ji Zhu; Allison R Altman; Wei-Ju Tseng; Yejia Zhang; Sunday O Akintoye; Keith Cengel; X Sherry Liu; Ling Qin
Journal:  Bone       Date:  2014-07-01       Impact factor: 4.398

5.  Parathyroid hormone reverses radiation induced hypovascularity in a murine model of distraction osteogenesis.

Authors:  Stephen Y Kang; Sagar S Deshpande; Alexis Donneys; Jose J Rodriguez; Noah S Nelson; Peter A Felice; Douglas B Chepeha; Steven R Buchman
Journal:  Bone       Date:  2013-05-01       Impact factor: 4.398

6.  Parathyroid Hormone (1-34) Transiently Protects Against Radiation-Induced Bone Fragility.

Authors:  Megan E Oest; Kenneth A Mann; Nicholas D Zimmerman; Timothy A Damron
Journal:  Calcif Tissue Int       Date:  2016-02-04       Impact factor: 4.333

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.